OPX Biotechnologies (Boulder, CO) a development-stage biofuels company using synthetic biology to engineer the microbes as a bio-acrylic renewable fuel source, closed a $36.5M Series C financing. Participants include US Renewables Group, DBL Investors, Mohr Davidow Ventures, Braemar Energy Ventures, Altira Group and X/Seed Capital.
Thanx for your patience as we catch-up.

Surefire Medical (Westminster, CO) a development-stage medical device company focused on interventional radiology embolic agent delivery, closed a $6.1M Series A financing. Participants include Partisan Management Group and High Country Venture.

Mosaic Bioscience (Boulder, CO) a development-stage synthetic materials company focused on tissue and bone regeneration, closed a $1M Series A financing. Participants include Morgenthaler, HealthCare Ventures and High Country Venture.

Precision Biopsy (Aurora, CO) a development-stage diagnostics company focused on advanced spectroscopy imaging and tissue biopsy for the diagnosis of prostate cancer, closed a $2.5M Series A financing. Participants include Allied Minds.

PanTheryx (Boulder, CO) a commercial-stage pharmaceutical company focused on the acquisition, development and commercialization of pain, inflammation, GERD, rhinitis and peripheral neuropathy products for the Indian healthcare market, closed a $1M Series A financing. Participants were not identified.

Accera (Broomfield, CO) a commercial-stage biotechnology company that developed and markets Axona for the dietary management of metabolic processes associated with mild to moderate Alzheimer’s disease, closed a $11M Series D financing. Participants were not identified, prior investors have include Inventages Venture Capital, POSCO BioVentures and Bloodstone Ventures.

Biodesix (Broomfield, CO) a commercial-stage personalized medicine company focused on diagnostic products that inform treatment decisions and patient care, whose initial product, VeriStrat, predicts response to the targeted therapy erlotinib in patients with advanced NSCLC, closed a $7.1M Series C financing. Participants were not identified.

Cylene Pharmaceuticals (San Diego, CA) a clinical-stage small molecule company focused on multiple myeloma, closed a $12M Series D financing. Participants include Sanderling Ventures, HBM BioVentures, Novartis Venture Fund, BioVentures Investors, Lilly Ventures, Mitsui & Co. and Morningside Venture Investments.

N30 Pharma (Boulder, CO) a preclinical-stage biopharmaceutical company focused on small molecules inhibting GSNOR for the potential treatment of asthma, COPD, inflammatory bowel disease and heart failure, closed a $10M Series B financing. Participants include Deerfield Management, Tiger Management, Bridger Capital and Swift Current Partners.

GlobeImmune (Lousiville, CO) a clinical-stage biopharmaceutical company developing a therapeutic vaccine platform focused on pancreatic cancer and hepatitis C, Closed a $17.5M Series E financing. Participants include Generali Financial Holding, BSI, Celgene, Wexford Capital, Mellon Family Investment Company, Eminent Venture Capital, Boston Life Science Venture, WRF Capital, Partners Healthcare, Yasuda, Genentech, Biogen Idec, CIDC, PAC-LINK [...]

Medivance (Louisville, KY) a commercial-stage device company focused on non-invasive core temperature management, closed a $8.1M Series E financing. Participants include Quellos Private Capital, MDY Healthcare, Cross Atlantic Partners, Skyline Ventures, Camden Partners, Partisan Management Group, Nikko Synergy Ventures, Kimberly-Clark, CSFB Private Equity and New England Capital Partners.

Clovis Oncology (Boulder, CO) an entity focused on licensing or acquiring rights to oncology compounds in all stages of clinical development, closed a $145M Series A financing. Participants include Domain Associates, New Enterprise Associates, Versant Ventures, Aberdare Ventures, Abingworth, Frazier Healthcare Ventures, and ProQuest Investments.

OPX Biotechnologies (Boulder, CO) a research-stage biofuels company using synthetic biology to engineer the microbes as a renewable fuel source, added to their Series B financing bringing the round up to $17.5M. Participants include Braemar Energy Ventures, Altira Group, Mohr Davidow Ventures and X/Seed Capital.